Brokerages Set Monopar Therapeutics Inc. (NASDAQ:MNPR) PT at $106.20

by · The Cerbat Gem

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) have been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $106.20.

A number of brokerages recently weighed in on MNPR. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. Barclays set a $125.00 price objective on Monopar Therapeutics and gave the company an “overweight” rating in a research report on Monday, October 13th. Oppenheimer set a $115.00 target price on Monopar Therapeutics and gave the stock an “outperform” rating in a report on Thursday, October 2nd. Leerink Partnrs raised Monopar Therapeutics to a “strong-buy” rating in a research report on Monday, November 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Wednesday, October 8th.

Check Out Our Latest Stock Report on Monopar Therapeutics

Monopar Therapeutics Stock Up 4.0%

Shares of MNPR stock opened at $68.63 on Monday. The stock has a 50-day simple moving average of $81.44 and a 200 day simple moving average of $59.04. The stock has a market capitalization of $458.65 million, a P/E ratio of -19.95 and a beta of 1.46. Monopar Therapeutics has a fifty-two week low of $21.00 and a fifty-two week high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, sell-side analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Buying and Selling

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of the firm’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total value of $35,000,066.69. Following the completion of the transaction, the insider directly owned 272,026 shares in the company, valued at $17,303,573.86. This trade represents a 66.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP acquired a new position in Monopar Therapeutics in the 3rd quarter worth approximately $18,904,000. Vanguard Group Inc. lifted its holdings in shares of Monopar Therapeutics by 140.7% in the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock valued at $17,005,000 after purchasing an additional 121,729 shares in the last quarter. Deerfield Management Company L.P. acquired a new stake in shares of Monopar Therapeutics in the third quarter worth $13,048,000. TCG Crossover Management LLC purchased a new position in shares of Monopar Therapeutics during the third quarter valued at $12,496,000. Finally, ADAR1 Capital Management LLC grew its holdings in shares of Monopar Therapeutics by 28.7% during the third quarter. ADAR1 Capital Management LLC now owns 129,999 shares of the company’s stock valued at $10,617,000 after buying an additional 29,025 shares in the last quarter. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

(Get Free Report)

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

Read More